Philip Cohen

This inventor holds 12 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: University of Dundee, Centre National De La Recherche Scientifique, Dana-Farber-Cancer Institute Inc.. Active years: 2002-2019.

USPTO Granted Patents = 12 (Patent Applications = 1)

% Patents Active = 50.0

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 70(Granted Patents)

Location History:

Invergowrie, GB (2011)
Dundee, GB (2002 - 2019)

Company Filing History:

Centre National De La Recherche Scientifique

patents

2 out of 1,264

Dana-Farber-Cancer Institute Inc.

Medical Research Council

patents

6. 1 out of 1

Medical Research Council London

Université Blaise Pascal - Clermont-Ferrand Ii

patents

where one patent can have more than one assignee

Years Active: 2002-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10233157 - SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder (2019-03-19),

2. 9670165 - SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder (2017-06-06),

3. 8999955 - Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological (2015-04-07),

4. 8481586 - [object Object] (2013-07-09),

5. 7897371 - Activation of mutated RAC-PK (2011-03-01),

6. 7727950 - Methods and reagents for assaying protein kinase activity (2010-06-01),

7. 7122360 - Polypeptides, polynucleotides and uses thereof (2006-10-17),

8. 7083511 - Methods (2006-08-01),

9. 6884600 - Protein phosphatase-1 catalytic subunit interactions (2005-04-26),

10. 6686467 - Amide derivatives for the treatment of diseases mediated by cytokines (2004-02-03),

11. 6617117 - MAP kinases: polypeptides, polynucleotides and uses thereof (2003-09-09),

12. 6498274 - Amide derivatives for the treatment of diseases mediated by cytokines (2002-12-24),

Title: Philip Cohen: The Innovative Pioneer in Technology

Introduction:

Philip Cohen, a visionary inventor hailing from Dundee, GB, is renowned for his relentless pursuit of innovation and his outstanding contributions to the realm of technology. With 12 patents to his name, Philip Cohen stands as a true pioneer in his field, inspiring countless inventors to push boundaries and strive for excellence.

Latest Patents:

Among Philip Cohen's latest patents is the groundbreaking discovery of SIK inhibitors for treating inflammatory and immune disorders. His work focuses on how salt inducible kinases suppress the formation of anti-inflammatory molecules, shedding light on potential treatments for conditions like inflammatory bowel disease and autoimmune disorders.

Career Highlights:

Throughout his illustrious career, Philip Cohen has made significant strides in the field of technology. Having worked with prestigious institutions such as the University of Dundee and Dana-Farber-Cancer Institute Inc., he has been at the forefront of cutting-edge research and development.

Collaborations:

Philip Cohen's impact extends beyond his individual achievements, as evidenced by his collaborations with esteemed colleagues like Kristopher Clark and Hwan Geun Choi. Together, they have spearheaded innovative projects that have pushed the boundaries of technology and paved the way for groundbreaking discoveries.

Conclusion:

In conclusion, Philip Cohen's unwavering dedication to innovation and his remarkable contributions to the world of technology make him a true luminary in his field. His work serves as an inspiration to future generations of inventors, encouraging them to think outside the box and strive for excellence in their pursuits.